About this Journal Submit a Manuscript Table of Contents
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 412486, 11 pages
http://dx.doi.org/10.1155/2012/412486
Review Article

SPECT Molecular Imaging in Parkinson's Disease

Ling Wang,1,2,3,4,5 Qi Zhang,2 Huanbin Li,2 and Hong Zhang1,3,4,5

1Department of Nuclear Medicine, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang 310009, China
2Department of Nuclear Medicine, Wenzhou Medical College, Wenzhou, China
3Zhejiang University Medical PET Center, Zhejiang University, Hangzhou, China
4Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou, China
5Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou, China

Received 3 January 2012; Accepted 29 January 2012

Academic Editor: Mei Tian

Copyright © 2012 Ling Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Hughes, S. E. Daniel, L. Kilford, and A. J. Lees, “Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 3, pp. 181–184, 1992. View at Scopus
  2. V. Ruipérez, F. Darios, and B. Davletov, “Alpha-synuclein, lipids and Parkinson's disease,” Progress in Lipid Research, vol. 49, no. 4, pp. 420–428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. L. Leong, R. Cappai, K. J. Barnham, and C. L. L. Pham, “Modulation of α-synuclein aggregation by dopamine: a review,” Neurochemical Research, vol. 34, no. 10, pp. 1838–1846, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Bellucci, G. Collo, I. Sarnico, L. Battistin, C. Missale, and P. Spano, “Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation,” Journal of Neurochemistry, vol. 106, no. 2, pp. 560–577, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Braak, K. Del Tredici, U. Rüb, R. A. I. de Vos, E. N. H. Jansen Steur, and E. Braak, “Staging of brain pathology related to sporadic Parkinson's disease,” Neurobiology of Aging, vol. 24, no. 2, pp. 197–211, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. J. P. Larsen, A. G. Beiske, S. I. Bekkelund et al., “Motor symptoms in Parkinson's disease,” Tidsskrift for den Norske Laegeforening, vol. 128, no. 18, pp. 2068–2071, 2008. View at Scopus
  7. R. F. Peppard, W. R. W. Martin, G. D. Carr et al., “Cerebral glucose metabolism in Parkinson's disease with and without dementia,” Archives of Neurology, vol. 49, no. 12, pp. 1262–1268, 1992. View at Scopus
  8. A. Kummer, P. Scalzo, F. Cardoso, and A. L. Teixeira, “Evaluation of fatigue in Parkinson's disease using the Brazilian version of Parkinson's Fatigue Scale,” Acta Neurologica Scandinavica, vol. 123, no. 2, pp. 130–136, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. R. D. S. Prediger, F. C. Matheus, M. L. Schwarzbold, M. M. S. Lima, and M. A. B. F. Vital, “Anxiety in Parkinson's disease: a critical review of experimental and clinical studies,” Neuropharmacology, vol. 62, no. 1, pp. 115–124, 2012. View at Publisher · View at Google Scholar
  10. D. Aarsland, K. Brønnick, J. P. Larsen, O. B. Tysnes, and G. Alves, “Cognitive impairment in incident, untreated parkinson disease: the norwegian parkwest study,” Neurology, vol. 72, no. 13, pp. 1121–1126, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Magerkurth, R. Schnitzer, and S. Braune, “Symptoms of autonomic failure in Parkinson's disease: prevalence and impact on daily life,” Clinical Autonomic Research, vol. 15, no. 2, pp. 76–82, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. S. S. O'Sullivan, K. Wu, M. Politis et al., “Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours,” Brain, vol. 134, part 4, pp. 969–978, 2011. View at Publisher · View at Google Scholar
  13. L. Morgante, C. Colosimo, A. Antonini et al., “Psychosis associated to Parkinson's disease in the early stages: relevance of cognitive decline and depression,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 83, no. 1, pp. 76–82, 2012. View at Publisher · View at Google Scholar
  14. H. W. Berendse, D. S. Roos, P. Raijmakers, and R. L. Doty, “Motor and non-motor correlates of olfactory dysfunction in Parkinson's disease,” Journal of the Neurological Sciences, vol. 310, no. 1-2, pp. 21–24, 2011. View at Publisher · View at Google Scholar
  15. M. Cohenpour and H. Golan, “Nuclear neuroimaging of dopamine transporter in Parkinsonism—role in routine clinical practice,” Harefuah, vol. 146, no. 9, pp. 698–702, 2007. View at Scopus
  16. J. Meara, B. K. Bhowmick, and P. Hobson, “Accuracy of diagnosis in patients with presumed Parkinson's disease,” Age and Ageing, vol. 28, no. 2, pp. 99–102, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Marshall and D. Grosset, “Role of dopamine transporter imaging in routine clinical practice,” Movement Disorders, vol. 18, no. 12, pp. 1415–1423, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Thobois, S. Guillouet, and E. Broussolle, “Contributions of PET and SPECT to the understanding of the pathophysiology of Parkinson's disease,” Neurophysiologie Clinique, vol. 31, no. 5, pp. 321–340, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. J. P. Seibyl, K. Marek, K. Sheff et al., “Iodine-123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients,” Journal of Nuclear Medicine, vol. 39, no. 9, pp. 1500–1508, 1998. View at Scopus
  20. G. Tissingh, J. Booij, P. Bergmans et al., “Iodine-123-N-ω-fluoropropyl-2/β-carbomethoxy3β-(4-iodophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease,” Journal of Nuclear Medicine, vol. 39, no. 7, pp. 1143–1148, 1998. View at Scopus
  21. K. Tatsch, J. Schwarz, P. D. Mozley et al., “Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [I123]IPT and single-photon emission tomography,” European Journal of Nuclear Medicine, vol. 24, no. 4, pp. 415–421, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Emond, D. Guilloteau, and S. Chalon, “PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter,” CNS Neuroscience and Therapeutics, vol. 14, no. 1, pp. 47–64, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Page, S. Chalon, P. Emond, J. M. Maloteaux, and E. Hermans, “Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4′-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells,” Neurochemistry International, vol. 40, no. 2, pp. 105–113, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Ziebell, “Evaluation of the superselective radioligand [I123]PE2I for imaging of the dopamine transporter in SPECT,” Danish Medical Bulletin, vol. 58, no. 5, Article ID B4279, 2011.
  25. W. S. Huang, Y. H. Chiang, J. C. Lin, Y. H. Chou, C. Y. Cheng, and R. S. Liu, “Crossover study of (99m)Tc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients,” Journal of Nuclear Medicine, vol. 44, no. 7, pp. 999–1005, 2003. View at Scopus
  26. H. F. Kung, S. Pan, M. P. Kung et al., “In vitro and in vivo evaluation of [I123]IBZM: a potential CNS D-2 dopamine receptor imaging agent,” Journal of Nuclear Medicine, vol. 30, no. 1, pp. 88–92, 1989. View at Scopus
  27. M. P. Kung, H. F. Kung, J. Billings, Y. Yang, R. A. Murphy, and A. Alavi, “The characterization of IBF as a new selective dopamine D-2 receptor imaging agent,” Journal of Nuclear Medicine, vol. 31, no. 5, pp. 648–654, 1990. View at Scopus
  28. M. S. Al-Tikriti, R. M. Baldwin, Y. Zea-Ponce et al., “Comparison of three high affinity SPECT radiotracers for the dopamine D2 receptor,” Nuclear Medicine and Biology, vol. 21, no. 2, pp. 179–188, 1994. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Matsumoto, A. Tanaka, N. Suzuki, S. Kondo, M. KatoAzuma, and Y. Yonekura, “Metabolism of I123-IBF in humans,” Kakuigaku, vol. 36, no. 2, pp. 169–177, 1999.
  30. R. A. Murphy, H. F. Kung, M. P. Kung, and J. Billings, “Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents,” Journal of Medicinal Chemistry, vol. 33, no. 1, pp. 171–178, 1990. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Spiegel, D. Hellwig, W. H. Jost, et al., “Cerebral and extracranial neurodegeneration are strongly coupled in Parkinson's disease,” The Open Neurology Journal, vol. 1, pp. 1–4, 2007.
  32. J. P. Seibyl, K. L. Marchek, D. Quinlan et al., “Decreased single-photon emission computed tomographic [I123]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease,” Annals of Neurology, vol. 38, no. 4, pp. 589–598, 1995. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Ichise, Y. J. Kim, J. R. Ballinger et al., “SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD,” Neurology, vol. 52, no. 6, pp. 1206–1214, 1999. View at Scopus
  34. C. C. P. Verstappen, B. R. Bloem, C. A. Haaxma, W. J. G. Oyen, and M. W. I. M. Horstink, “Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson's disease: an [I123]IBZM and [I123]FP-CIT SPECT study,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 4, pp. 502–507, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. K. H. Ma, W. S. Huang, C. H. Chen et al., “Dual SPECT of dopamine system using [(99m)Tc]TRODAT-1 and [I123]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys,” Nuclear Medicine and Biology, vol. 29, no. 5, pp. 561–567, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. H. T. S. Benamer, J. Patterson, D. J. Wyper, D. M. Hadley, G. J. A. Macphee, and D. G. Grosset, “Correlation of Parkinson's disease severity and duration with I123-FP-CIT SPECT striatal uptake,” Movement Disorders, vol. 15, no. 4, pp. 692–698, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Eggers, D. Kahraman, G. R. Fink, M. Schmidt, and L. Timmermann, “Akinetic-rigid and tremor-dominant Parkinson's disease patients show different patterns of FP-CIT Single photon emission computed tomography,” Movement Disorders, vol. 26, no. 3, pp. 416–423, 2011. View at Publisher · View at Google Scholar
  38. S. J. Kish, J. Tong, O. Hornykiewicz et al., “Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease,” Brain, vol. 131, part 1, pp. 120–131, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. F. Roselli, N. M. Pisciotta, M. Pennelli et al., “Midbrain SERT in degenerative parkinsonisms: a I123-FP-CIT SPECT study,” Movement Disorders, vol. 25, no. 12, pp. 1853–1859, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. K. L. Marek, J. P. Seibyl, S. S. Zoghbi et al., “[I123] β-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease,” Neurology, vol. 46, no. 1, pp. 231–237, 1996. View at Scopus
  41. J. Eerola, P. J. Tienari, S. Kaakkola, P. Nikkinen, and J. Launes, “How useful is [I123]β-CIT SPECT in clinical practice?” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 9, pp. 1211–1216, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. V. L. Marshall, C. B. Reininger, M. Marquardt et al., “Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [I123]FP-CIT SPECT,” Movement Disorders, vol. 24, no. 4, pp. 500–508, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Sawada, T. Oeda, K. Yamamoto et al., “Diagnostic accuracy of cardiac metaiodobenzylguanidine scintigraphy in Parkinson disease,” European Journal of Neurology, vol. 16, no. 2, pp. 174–182, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. J. Spiegel, M. O. Möllers, W. H. Jost et al., “FP-CIT and MIBG scintigraphy in early Parkinson's disease,” Movement Disorders, vol. 20, no. 5, pp. 552–561, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. K. L. Chou, H. I. Hurtig, M. B. Stern et al., “Diagnostic accuracy of [(99m)Tc]TRODAT-1 SPECT imaging in early Parkinson's disease,” Parkinsonism and Related Disorders, vol. 10, no. 6, pp. 375–379, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. G. Tissingh, P. Bergmans, J. Booij et al., “Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [I123]β-CIT SPECT,” Journal of Neurology, vol. 245, no. 1, pp. 14–20, 1998. View at Publisher · View at Google Scholar · View at Scopus
  47. L. Filippi, C. Manni, M. Pierantozzi et al., “I123-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson's disease with unilateral symptoms,” Nuclear Medicine Communications, vol. 26, no. 5, pp. 421–426, 2005. View at Publisher · View at Google Scholar · View at Scopus
  48. W. S. Huang, K. H. Ma, Y. H. Chou, C. Y. Chen, R. S. Liu, and J. C. Liu, “(99m)Tc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET,” Nuclear medicine communications, vol. 24, no. 1, pp. 77–83, 2003. View at Scopus
  49. W. S. Huang, S. Z. Lin, J. C. Lin, S. P. Wey, G. Ting, and R. S. Liu, “Evaluation of early-stage Parkinson's disease with (99m)Tc-TRODAT-1 imaging,” Journal of Nuclear Medicine, vol. 42, no. 9, pp. 1303–1308, 2001. View at Scopus
  50. G. Kägi, K. P. Bhatia, and E. Tolosa, “The role of DAT-SPECT in movement disorders,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 1, pp. 5–12, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Ishibashi, Y. Saito, S. Murayama et al., “Validation of cardiac I123-MIBG scintigraphy in patients with Parkinson's disease who were diagnosed with dopamine PET,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 1, pp. 3–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Sakakibara, H. Shinotoh, T. Uchiyama, M. Yoshiyama, T. Hattori, and T. Yamanishi, “SPECT imaging of the dopamine transporter with [I123]-β-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction,” Journal of the Neurological Sciences, vol. 187, no. 1-2, pp. 55–59, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Agid, “Parkinson's disease: pathophysiology,” The Lancet, vol. 337, no. 8753, pp. 1321–1324, 1991. View at Publisher · View at Google Scholar · View at Scopus
  54. A. M. M. Vlaar, T. de Nijs, A. G. H. Kessels et al., “Diagnostic value of I123-ioflupane and I123-iodobenzamide SPECT scans in 248 patients with Parkinsonian syndromes,” European Neurology, vol. 59, no. 5, pp. 258–266, 2008. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Contrafatto, G. Mostile, A. Nicoletti et al., “[I123]FP-CIT-SPECT asymmetry index to differentiate Parkinson's disease from vascular parkinsonism,” Acta Neurologica Scandinavica, In press. View at Publisher · View at Google Scholar
  56. M. Loberboym, T. A. Traves, E. Melamed, Y. Lampl, M. Hellman, and R. Djaldetti, “[I123]-EP/CIT SPECT imaging for distinguishing drug-induced Parkinsonism from Parkinson's disease,” Movement Disorders, vol. 21, no. 4, pp. 510–514, 2006. View at Publisher · View at Google Scholar
  57. F. J. Diaz-Corrales, S. Sanz-Viedma, D. Garcia-Solis, T. Escobar-Delgado, and P. Mir, “Clinical features and I123-FP-CIT SPECT imaging in drug-induced parkinsonism and Parkinson's disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 3, pp. 556–564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Cuberas-Borrós, C. Lorenzo-Bosquet, S. Aguadé-Bruix et al., “Quantitative evaluation of striatal I-123-FP-CIT uptake in essential tremor and parkinsonism,” Clinical Nuclear Medicine, vol. 36, no. 11, pp. 991–996, 2011. View at Publisher · View at Google Scholar
  59. A. C. Felicio, M. C. Shih, C. Godeiro-Junior, L. A. F. Andrade, R. A. Bressan, and H. B. Ferraz, “Molecular imaging studies in Parkinson disease reducing diagnostic uncertainty,” Neurologist, vol. 15, no. 1, pp. 6–16, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. S. Gilman, G. K. Wenning, P. A. Low et al., “Second consensus statement on the diagnosis of multiple system atrophy,” Neurology, vol. 71, no. 9, pp. 670–676, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. C. Scherfler, K. Seppi, E. Donnemiller et al., “Voxel-wise analysis of [I123]β-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease,” Brain, vol. 128, part 7, pp. 1605–1612, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. G. El Fakhri and J. Ouyang, “Dual-radionuclide brain SPECT for the differential diagnosis of parkinsonism,” Methods in Molecular Biology, vol. 680, pp. 237–246, 2011.
  63. A. Antonini, R. Benti, R. de Notaris et al., “I123-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy,” Neurological Sciences, vol. 24, no. 3, pp. 149–150, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Varrone, K. L. Marek, D. Jennings, R. B. Innis, and J. P. Seibyl, “[I123]β-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy,” Movement Disorders, vol. 16, no. 6, pp. 1023–1032, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. G. M. Knudsen, M. Karlsborg, G. Thomsen et al., “Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 31, no. 12, pp. 1631–1638, 2004. View at Publisher · View at Google Scholar · View at Scopus
  66. R. L. Swanson, A. B. Newberg, P. D. Acton et al., “Differences in [(99m)Tc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 32, no. 3, pp. 302–307, 2005. View at Publisher · View at Google Scholar · View at Scopus
  67. Y. J. Kim, M. Ichise, J. R. Ballinger et al., “Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP,” Movement Disorders, vol. 17, no. 2, pp. 303–312, 2002. View at Publisher · View at Google Scholar · View at Scopus
  68. G. Pöpperl, P. Radau, R. Linke, K. Hahn, and K. Tatsch, “Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism,” Nuclear Medicine Communications, vol. 26, no. 1, pp. 39–43, 2005. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Oyanagi, Y. Katsumi, T. Hanakawa et al., “Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [I123] iodobenzofuran single-photon emission computed tomography,” Journal of Neuroimaging, vol. 12, no. 4, pp. 316–324, 2002. View at Scopus
  70. V. M. Poblete Garcíau, A. García Vicente, S. Ruíz Solís et al., “SPECT with I123-IBZM: utility in differential diagnosis of degenerative Parkinsonisms and establishment of quantification method,” Revista Espanola de Medicina Nuclear, vol. 24, no. 4, pp. 234–243, 2005. View at Publisher · View at Google Scholar
  71. M. Südmeyer, C. Antke, T. Zizek et al., “Diagnostic accuracy of combined FP-CIT, IBZM, and MIBG scintigraphy in the differential diagnosis of degenerative parkinsonism: a multidimensional statistical approach,” Journal of Nuclear Medicine, vol. 52, no. 5, pp. 733–740, 2011. View at Publisher · View at Google Scholar
  72. M. Ziebell, B. B. Andersen, G. Thomsen et al., “Predictive value of dopamine transporter SPECT imaging with [I123]PE2I in patients with subtle parkinsonian symptoms,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 2, pp. 242–250, 2012. View at Publisher · View at Google Scholar
  73. D. Kahraman, C. Eggers, H. Schicha, L. Timmermann, and M. Schmidt, “Visual assessment of dopaminergic degeneration pattern in I123-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease,” Journal of Neurology, vol. 259, no. 2, pp. 251–260, 2011. View at Publisher · View at Google Scholar
  74. K. R. Kessler, N. Hamscho, B. Morales et al., “Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome,” Journal of Neural Transmission, vol. 112, no. 10, pp. 1345–1353, 2005. View at Publisher · View at Google Scholar · View at Scopus
  75. W. J. Hwang, W. J. Yao, S. P. Wey, and G. Ting, “Clinical and [(99m)Tc]TRODAT-1/[I123]IBZM SPECT imaging findings in dopa-responsive dystonia,” European Neurology, vol. 51, no. 1, pp. 26–29, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. O. Schilaci, A. Chiaravaloti, M. Pierantozzi et al., “Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with I123-FP-CIT SPECT,” International Journal of Molecular Medicine, vol. 28, no. 5, pp. 881–886, 2011. View at Publisher · View at Google Scholar
  77. C. Rossi, D. Frosini, D. Volterrani et al., “Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study,” European Journal of Neurology, vol. 17, no. 4, pp. 626–630, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. J. Spiegel, D. Hellwig, S. Samnick et al., “Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease,” Journal of Neural Transmission, vol. 114, no. 3, pp. 331–335, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. K. Marek, R. Innis, C. van Dyck et al., “[I123] β-CIT SPECT imaging assessment of the rate of Parkinson's disease progression,” Neurology, vol. 57, no. 11, pp. 2089–2094, 2001. View at Scopus
  80. A. Winogrodzka, P. Bergmans, J. Booij, E. A. van Royen, A. G. Janssen, and E. C. Wolters, “[I123]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease,” Journal of Neural Transmission, vol. 108, no. 8-9, pp. 1011–1019, 2001. View at Publisher · View at Google Scholar · View at Scopus
  81. A. Winogrodzka, P. Bergmans, J. Booij, E. A. van Royen, J. C. Stoof, and E. C. Wolters, “[I123]β-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 74, no. 3, pp. 294–298, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. J. P. Seibyl, K. Marek, K. Sheff et al., “Test/retest reproducibility of iodine-123-βCIT SPECT brain measurement of dopamine transporters in Parkinson's patients,” Journal of Nuclear Medicine, vol. 38, no. 9, pp. 1453–1459, 1997. View at Scopus
  83. W. Pirker, S. Djamshidian, S. Asenbaum et al., “Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal β-CIT SPECT study,” Movement Disorders, vol. 17, no. 1, pp. 45–53, 2002. View at Publisher · View at Google Scholar · View at Scopus
  84. G. K. Wenning, E. Donnemiller, R. Granata, G. Riccabona, and W. Poewe, “I123-β-CIT and I123-IBZM-SPECT scanning in levodopa-naive Parkinson's disease,” Movement Disorders, vol. 13, no. 3, pp. 438–445, 1998. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. H. Weng, T. C. Yen, M. C. Chen et al., “Sensitivity and specificity of (99m)Tc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects,” Journal of Nuclear Medicine, vol. 45, no. 3, pp. 393–401, 2004. View at Scopus
  86. W. J. Weiner, “Early diagnosis of Parkinson's disease and initiation of treatment,” Reviews in Neurological Diseases, vol. 5, no. 2, pp. 46–53, 2008, quiz 54-55. View at Scopus
  87. K. E. Lyons and R. Pahwa, “Diagnosis and initiation of treatment in Parkinson's disease,” International Journal of Neuroscience, vol. 121, supplement 2, pp. 27–36, 2011. View at Publisher · View at Google Scholar
  88. J. Schwarz, K. Tatsch, T. Gasser, G. Arnold, and W. H. Oertel, “[I123]IBZM binding predicts dopaminergic responsiveness in patients with parkinsonism and previous dopaminomimetic therapy,” Movement Disorders, vol. 12, no. 6, pp. 898–902, 1997. View at Publisher · View at Google Scholar · View at Scopus
  89. A. Hertel, M. Weppner, H. Baas et al., “Quantification of IBZM dopamine receptor SPET in de novo Parkinson patients before and during therapy,” Nuclear Medicine Communications, vol. 18, no. 9, pp. 811–822, 1997. View at Scopus
  90. D. Contrafatto, G. Mostile, A. Nicoletti et al., “Single photon emission computed tomography striatal asymmetry index may predict dopaminergic responsiveness in Parkinson disease,” Clinical Neuropharmacology, vol. 34, no. 2, pp. 71–73, 2011.
  91. P. O. Fernagut, Q. Li, S. Dovero et al., “Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys,” PLoS ONE, vol. 5, no. 11, Article ID e14053, 2010. View at Publisher · View at Google Scholar · View at Scopus
  92. R. B. Innis, K. L. Marek, K. Sheff et al., “Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [I123]β-CIT,” Movement Disorders, vol. 14, no. 3, pp. 436–442, 1999. View at Publisher · View at Google Scholar · View at Scopus
  93. W. J. Hwang, W. J. Yao, S. P. Wey, L. H. Shen, and G. Ting, “Downregulation of striatal dopamine D2 receptors in advanced Parkinson's disease contributes to the development of motor fluctuation,” European Neurology, vol. 47, no. 2, pp. 113–117, 2002. View at Publisher · View at Google Scholar · View at Scopus
  94. P. K. Morrish, G. V. Sawle, and D. J. Brooks, “Regional changes in [18F]dopa metabolism in the striatum in Parkinson's disease,” Brain, vol. 119, part 6, pp. 2097–2103, 1996. View at Scopus
  95. K. Ito, P. K. Morrish, J. S. Rakshi et al., “Statistical parametric mapping with 18F-dopa PET shows bilaterally reduced striatal and nigral dopaminergic function in early Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 66, no. 6, pp. 754–758, 1999. View at Scopus
  96. W. Koch, C. Hamann, P. E. Radau, and K. Tatsch, “Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 8, pp. 1265–1273, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. P. K. Morrish, G. V. Sawle, and D. J. Brooks, “Clinical and [(18F)]dopa PET findings in early Parkinson's disease,” Journal of Neurology Neurosurgery and Psychiatry, vol. 59, no. 6, pp. 597–600, 1995. View at Scopus
  98. J. V. Hindle, “Ageing, neurodegeneration and Parkinson's disease,” Age and Ageing, vol. 39, no. 2, pp. 156–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Booij and H. W. Berendse, “Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway,” Journal of the Neurological Sciences, vol. 310, no. 1-2, pp. 40–43, 2011. View at Publisher · View at Google Scholar
  100. I. U. Isaias, R. Benti, R. Cilia et al., “[I123]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset,” NeuroReport, vol. 18, no. 14, pp. 1499–1502, 2007. View at Publisher · View at Google Scholar · View at Scopus
  101. R. Buchert, G. Berding, F. Wilke et al., “IBZM tool: a fully automated expert system for the evaluation of IBZM SPECT studies,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 33, no. 9, pp. 1073–1083, 2006. View at Publisher · View at Google Scholar · View at Scopus
  102. H. Fukuyama, “Is I123-MIBG cardiac scintigraphy a surrogate marker for Parkinson's disease?” European Journal of Nuclear Medicine and Molecular Imaging, vol. 37, no. 1, pp. 1–2, 2010. View at Publisher · View at Google Scholar · View at Scopus